Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC)

被引：1
|
作者：
Mustacchi, G.
Bines, J.
Alba, E.
Cortes, P.
Doval, D.
de Ducla, S.
Button, P.
Gligorov, J.
机构：
[1] Univ Trieste, Trieste, Italy
[2] Inst Nacl Canc, Rio De Janeiro, Brazil
[3] Hosp Univ Clin Virgen Victoria, Malaga, Spain
[4] Univ Hosp Santa Maria, Lisbon, Portugal
[5] Rajiv Gandhi Canc Inst & Res Ctr, Delhi, India
[6] F Hoffmann Roche Ltd, Basel, Switzerland
[7] Roche Prod Ltd, Dee Why, Australia
[8] IC UPMC, APHP Tenon, Paris, France
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P5-15-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-15-06
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC)
    Gligorov, Joseph
    Bines, Jose
    Alba, Emilio
    Mustacchi, Giorgio
    Cinieri, Saverio
    Gupta, Vineet
    Pierga, Jean-Yves
    Bozcuk, Hakan
    Gaafar, Rabab
    Gupta, Sudeep
    Vivanco, Guillermo Lopez
    Wang, Xiaojia
    Costa, Romulo
    Altundag, Kadri
    Chmielowska, Ewa
    de Ducla, Sabine
    Freudensprung, Ulrich
    Cortes, Paulo
    Doval, Dinesh
    CANCER RESEARCH, 2015, 75
  • [2] Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Zielinski, C. C.
    Lang, I.
    Inbar, M.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Zvirbule, Z.
    Steger, G. G.
    Melichar, B.
    Pienkowski, T.
    Sirbu, D.
    Petruzelka, L.
    Eniu, A.
    Nisenbaum, B.
    Dank, M.
    Anghel, R.
    Messinger, D.
    Brodowicz, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S263 - S264
  • [3] Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast can
    Doval, Dinesh
    Cinieri, Saverio
    Bozcuk, Hakan
    Pierga, Jean-Yves
    Altundag, Kadri
    Wang, Xiaojia
    Gupta, Sudeep
    Lopez Vivanco, Guillermo
    Gupta, Vineet
    Chmielowska, Ewa
    Bines, Jose
    Montcuquet, Philippe
    Namour, Alfred
    Alba, Emilio
    Mustacchi, Giorgio
    Cortes, Paulo
    de Ducla, Sabine
    Freudensprung, Ulrich
    Fallowfield, Lesley
    Gligorov, Joseph
    CANCER RESEARCH, 2015, 75
  • [4] Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Vrdoljak, E.
    Marschner, N.
    Zielinski, C.
    Gligorov, J.
    Cortes, J.
    Puglisi, F.
    Aapro, M.
    Fallowfield, L.
    Fontana, A.
    Inbar, M.
    Kahan, Z.
    Welt, A.
    Levy, C.
    Brain, E.
    Pivot, X.
    Putzu, C.
    Gonzalez-Martin, A.
    Ebel, K.
    Easton, V.
    von Minckwitz, G.
    CANCER RESEARCH, 2016, 76
  • [5] BEVACIZUMAB-CAPECITABINE (BEV-CAP) AFTER INITIAL 1ST-LINE BEVACIZUMAB-DOCETAXEL (BEV-DOC) IN PATIENTS (PTS) WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC): SAFETY ANALYSIS OF THE IMELDA TRIAL
    Gligorov, J.
    Alba-Conejo, E.
    Bines, J.
    Cortes, P. A.
    Doval, D. C.
    Jiang, Z.
    Freudensprung, U.
    Mustacchi, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 128 - 128
  • [6] Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC).
    Brufsky, Adam M.
    Hurvitz, Sara A.
    Perez, Edith A.
    Yamamoto, Hideharu
    Valero, Vicente
    O'Neill, Vincent
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [7] Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) plus bevacizumab (BEV): Results of a subanalysis of the randomized phase III CECOG TURANDOT trial
    Christoph, Zielinski C.
    Istvan, Lang
    Semir, Beslija
    Zsuzsanna, Kahan
    Inbar, Moshe J.
    Salomon, Stemmer M.
    Rodica, Anghel
    Damir, Vrbanec
    Diethelm, Messinger
    Thomas, Brodowicz
    CANCER RESEARCH, 2015, 75
  • [8] Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit?
    Kuemmel, S.
    Jackisch, C.
    Mueller, V.
    Schneeweiss, A.
    Klawitter, S.
    Lux, M. P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)
    Miles, D. W.
    De Haas, S. L.
    Romieu, G.
    Chan, A.
    Dirix, L.
    Cortess, J.
    Delmar, P. R.
    Scherer, S. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S176 - S176
  • [10] Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Puglisi, Fabio
    Cortes, Javier
    Vrdoljak, Eduard
    Gligorov, Joseph
    Marschner, Norbert
    Zielinski, Christoph
    de Laurentiis, Michele
    Brain, Etienne
    Levy, Christelle
    Welt, Anja
    Kahan, Zsuzsanna
    Inbar, Moshe
    de Ducla, Sabine
    Freudensprung, Ulrich
    von Minckwitz, Gunter
    CANCER RESEARCH, 2015, 75
12345